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Abstract
Megaloblastic anemia is a multisystem disorder, which can easily be diagnosed with high 
index of suspicion and by correct application of its pathogenetic mechanisms. Any factor 
inhibiting deoxyribonucleic acid (DNA) synthesis, drugs (medications), infections like 
human immunodeficiency virus (HIV) and gas like nitrous oxide will cause megaloblas-
tosis. However, poor diet, problems with absorption, transportation and metabolism of 
the vitamins, as well as factors that increase demand and ultimately exhaust the store 
of the vitamins like chronic hemolytic states, pregnancy, malignancies happen to be the 
commonest causes of megaloblastic anemia. A complete blood count, blood and marrow 
films review reflect the typical pathognomonic cytologic appearance of megaloblastic 
anemia. Logically selected biochemical tests help in establishing diagnosis through deter-
mination of serum levels of both folate and cobalamin and assessment of the metabolites, 
which are considered to be more sensitive and specific. Also, full endoscopic studies are 
required to confirm the presence of disorders of gastrointestinal tract responsible for 
impaired absorption. Clinical features are subtle and widely varied. It is highly amenable 
to therapy once the primary cause is established and managed. Appropriate replace-
ment therapy of deficient nutrient, cobalamin or folate or both, easily corrects anemia. 
Pernicious anemia often requires lifelong therapy with parenteral cobalamin.
Keywords: anemia, megaloblast, blood and marrow smears review, neuropathies, 
replacement therapy
1. Introduction
Anemia, technically, describes a condition in which an individual’s hemoglobin level (or 
hematocrit) falls two standard deviations below the average mean of normal for individuals 
of same age, sex, and altitude [1, 2]. The functional consequence of anemia decreased oxygen 
carrying capacity of the blood and general tissue hypoxia.
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Megaloblastic anemia refers to a group of anemias that have in common a selective reduction 
in the rate of deoxyribonucleic acid (DNA) synthesis; however, transcription, translation, and 
protein synthesis proceed normally. Consequently, a resultant unbalanced cell growth ensues 
and the dichotomy between the rates of cytoplasmic and nuclear maturation widens with 
each division during erythropoiesis until eventually the cell either dies or omits terminal divi-
sion making it to survive as oversized end stage cell (macrocytes) with a shortened lifespan. 
Therefore, the retarded DNA synthesis leads to accumulation of dead and dying megaloblasts 
in the marrow, creating a spurious appearance of marrow hyperplasia but with a gradual 
reduction in the number of matured cells being pushed out and eventually progressed to pan-
cytopenia. The megaloblastic anemias are caused by vitamin B
12
 deficiency, folate deficiency, 
or by related conditions that caused impaired DNA synthesis.
1.1. History
Many researchers sequentially contributed to the discovery and identification of its etiology. 
Addison in 1849 was the first to characterize it as anemia, general languor, and debility [3]. 
In 1877, Osler and Gardnerin discovered its association with neuropathy and its association 
with myelopathy was documented 10 years later by Lichtheim. Megaloblasts were identified by 
Ehrlic in 1880 while the abnormalities in leukocytes were described in 1920. It was confirmed by 
Minot and Murphy that the disease is reversible by the intake of large amount of liver [4]. Castle, 
in 1929, discovered the presence of “intrinsic factor” in gastric acid that facilitates the absorption 
of the “extrinsic factor” [5]. The structure of vitamin B
12
 was later identified by Hodgkin and this 
earned him a Nobel Prize [6]. However, it was Herbert, in 1948, who discovered the structure of 
folic acid and described its link with the causation of megaloblastic anemia [7].
2. Epidemiology
Epidemiological studies on megaloblastic anemia in Nigeria and in Africa are sparse. 
However, the frequency of megaloblastosis is highest in countries in which malnutrition is 
rampant and routine vitamin supplementation for elderly individuals and pregnant woman 
is not available. Faulty preparations of foods and increased demand for folate during preg-
nancy are the most common causes of megaloblastic anemias.
About 1 in 7500 people develops pernicious anemia in the US per year but this has been modi-
fied by current fortification of foods and vitamin supplementations in elderly patients in the 
US. International statistics showed that pernicious anemia and folate deficiency usually occur 
in individuals older than 40 years and the prevalence increases with older populations. The 
incidence of pernicious anemia is reported to be higher in Sweden, Denmark, and United 
Kingdom than in other developed countries [8].
3. Physiology of cobalamin and folate
Vitamin B
12
 consists of a corrin ring with a cobalt atom in its center attached to a nucleotide por-
tion and they are termed cobalamins. The biologically inactive pharmacologic preparations 
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of vitamin B
12
 include cyanocobalamin and hydroxocobalamin whereas adenosylcobalamin 
and methylcobalamin that are generated through enzymatic synthesis are the biologically 
active forms, whereas adenosyl-cobalamin is the tissue form of vitamin B
12
, methylcobalamin 
circulates in blood. Although a normal diet provides a large excess of vitamin B
12
, the daily 
requirement is about 1–2 μg in adults. In the process of digestion, R-protein, either of salivary 
or parietal cells origin, binds to liberated cobalamin from complex dietary protein through 
the action of gastric secretion made up of pepsin and hydrochloric acid. The cobalamin-R 
protein complex is degraded pancreatic secretions in the duodenum to release free cobalamin 
that then binds to intrinsic factor that was secreted in the stomach. The cobalamin-intrinsic 
factor complex is now transported to the terminal ileum where absorption takes place. Failure 
of physiological activity at any of these points results in megaloblastic anemia. Following 
absorption, the released vitamin binds a transport protein called transcobalamin (TCII), 
which transports the vitamin to enterohepatic circulation. Vitamin B
12
 is stored primarily in 
the liver in an amount of 2–3 mg, which is 1000-fold in excess of daily requirement.
The physiologic role of vitamin B
12
 include:
a. Conversion of methyl-malonyl-coenzyme A (CoA) to succinyl CoA by adenosyl cobalamin.
b. Conversion of homocysteine to methionine.
c. Synthesis of S-adenosyl-methionine.
3.1. Physiology of folate (pteroyl glutamic acid)
Folic acid, a composite molecule consists of pteridine, p-amino benzoic acid, and glutamic 
acid. Folates are available as polyglutamates in many foods like the green leafy vegetables, 
yeast, and liver. However, overcooking easily destroys the folate. Folate is absorbed as mono-
glutamates in the upper jejunum. The daily requirement of folate is 150 μg and the body 
stores of folate are sufficient for 6 months. The major intracellular compounds are folate poly-
glutamates with attached additional glutamates. Folates are essential in many biochemical 
reactions like synthesis of purines, thymine, and deoxyribonucleic acid (DNA).
4. Etiology and pathogenesis
The principal causes of megaloblastic anemia in clinical practice are folate and cobalamin 
deficiency either directly or indirectly (see Table 1).
4.1. Major causes of cobalamin deficiency include
Dietary: Dietary cause of cobalamin deficiency is rare except in strict vegetarians who avoid 
taking meat, eggs, and dairy products.
Problems with cobalamin absorption: Atrophic gastritis and achlorhydria, which commonly 
occur in elderly people are the two conditions which are responsible for impaired release of 
cobalamins bound to food. Hence, cobalamin is not released from food for absorptive process.
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Also, autoimmune destruction of gastric parietal cells may lead to failure of intrinsic factor 
production. This condition is called pernicious anemia. Pernicious anemia is recognized as 
the best-known cause of cobalamin deficiency. It is diagnosed in 1% of people older than 60 
years and the incidence is slightly higher in women than in men.
Inhibition of intrinsic factor production can also be caused by H
2
 antagonists.
The release of cobalamin from R-proteins can also be inhibited by the alkaline environment in 
the small intestine emanating from pancreatic insufficiency.
On the contrary, the acidic environment seen in conditions like Zollinger Ellison syndrome, 
also prevents binding of cobalamin to intrinsic factor hence leading to diminished binding to 
intrinsic factor and ultimate interference with cobalamin absorption.
The disorders of the terminal ileum, site of uptake of cobalamin-intrinsic factor complex, can 
cause cobalamin deficiency. Disorders that can possibly affect the terminal ileum include trop-
ical sprue, inflammatory bowel disease, lymphoma, as well as ileal resection. Autoimmune 
destruction of the ileal receptor, cubilin, as found in Imerslund Grasbeck syndrome equally 
distrupts the uptake of cobalamin bound to intrinsic factor.
Also, bacteria colonization can occur in intestines deformed by strictures, surgical blind loops, 
scleroderma, inflammatory bowel disease, or amyloidosis blind loop syndrome can result to 
I. Cobalamin deficiency II. Folate deficiency III. Drug-induced 
suppression of DNA 
synthesis
IV. Inborn errors
(i) Dietary deficiency
(ii) Deficiency of gastric IF
Pernicious anemia or 
gastrectomy
(iii) Intestinal 
malabsorption
Ileal resection or ileitis
Familial selective 
cobalamin malabsorption
Competitive parasites or 
infections
Fish tapeworm
Bacteria overgrowth in 
malformed small bowel
(iv) Increased Requirement
(i) Dietary deficiency
(ii) Impaired absorption
Sprue
Extensive small bowel 
disease or resection
Intestinal short circuits
Anticonvulsants and oral 
contraceptives
(iii) Increased requirement
Pregnancy
Hemolytic anemia
Myeloproliferative and 
other hyperproliferative 
disorders
(i) Folate antagonists
(ii) Metabolic inhibitors 
of purine pyrimidine 
thymidylate synthesis
Other inhibitors
(iii) Alkylating agents
D. Nitrous oxide
(IV) Inborn errors
a. Defective transport of 
cobalamin
b. Defective cobalamin 
utilization
c. Defective folate 
metabolism
d. Hereditary orotic 
aciduria
e. Lesch-Nyhan 
syndrome
(i) Defective transport of 
cobalamin
(ii) Defective cobalamin 
utilization
(iii) Defective folate 
metabolism
(iv) Hereditary orotic 
aciduria
E. Lesch-Nyhan syndrome
Table 1. Pathogenetic classification of megaloblastic anemia [9].
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cobalamin deficiency. In this condition, bacteria competes with the host for cobalamin for the 
uptake of cobalamin bound to intrinsic factor.
Fish tapeworm such as Diphyllobothrium latum infestation, which is common in places like 
Canada, Alaska, and the Baltic sea, feeds on cobalamin in the intestine thereby reducing the 
amount of cobalamin available for ingestion by the host.
Miscellaneous causes of cobalamin deficiency include exposure to nitrous oxide, which 
through oxidative inactivation of cobalamin causes megaloblastosis. Prolonged exposure to 
nitrous oxide can lead to severe mental and neurological disorders. Various medications like 
purine analogs (six mercaptopurine, six tioguanine), pyrimidine analogs (five fluorouracil 
and five azacytidine), and drugs that affect cobalamin metabolism like P-aminosalicylic acid, 
phenformin, and metformin that can cause cobalamin deficiency.
4.2. Major causes of folate deficiency
The main cause of loss of folate from food is poor food preparation through excessive dilution 
of food in water, through excessive heating, and subsequent inactivation of folate since folate 
is thermolabile. However, food fortification with folate and other vitamins are circumventing 
this problem in developed countries. This has to be aggressively promoted in many develop-
ing countries.
The storage of folate is for about 4 weeks after which folate deficiency sets in if folate intake is 
stopped. The daily requirement for adult is about 0.4 mg/day.
Folate deficiency occurs in situations where there is impaired absorption due to certain intes-
tinal disorders like tropical sprue, nontropical sprue (celiac disease), amyloidosis, and inflam-
matory bowel disease.
Folate deficiency occurs in situations where there is increased physiologic demand for folate 
like chronic hemolytic states like sickle cell anemia, hereditary spherocytosis, and elliptocy-
tosis; pregnancy, lactation, rapid growth, hyperalimentation, renal dialysis, where there is 
escalated loss of rapidly dividing cells like psoriasis and exfoliative dermatitis.
Also, medications such as phenytoin, metformin, phenobarbitone, dihydrofolate reductase, 
folate inhibitors like trimethoprim and pyrimethamine, methotrexate, sulphonamides, can 
cause folate deficiency.
Megaloblastic changes in human immunodeficiency virus (HIV) infection and myelodysplas-
tic disorders are due to direct effect on deoxyribonucleic acid (DNA) in hemopoietic and other 
rapidly dividing cells.
4.3. Pathophysiology of megaloblastic anemia
The two vitamins, that is, folate and cobalamin act synergistically in generating the thymidylic 
acid used for DNA synthesis. Therefore, in cobalamin deficiency, the megaloblastic arrest is 
actually caused by a deficit in folate utilization. As shown in Figure 1 (activated methyl cycle), 
methionine is generated by transfer of methylene group from N5-methyl tetrahydrofolate 
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(FH4) to homocysteine using the enzyme methyl transferase (Methionine synthase). In this 
biochemical process, methylcobalamin is the factor that assists in methyl transfer as coen-
zyme form of cobalamin. This is why the morphological abnormalities emanating from either 
cobalamin or folate deficiency appear exactly alike.
5. Clinical features
Megaloblastic anemias, irrespective of the cause, share certain general features. The anemia 
develops slowly with little or no symptoms until the hematocrit is severely depressed and 
at this point, symptoms like weakness, palpitation, fatigue, light headedness, and short-
ness of breath occur. Severe pallor and light jaundice combine to produce a telltale lemon 
yellow skin. Slight differences occur in clinical symptoms and signs of megaloblastic ane-
mia depending on whether it is caused by folate deficiency or by vitamin B
12
 deficiency. In 
folate deficiency, main clinical features include anemic syndrome, pallor, icterus, hunter's 
syndrome, nail pigmentation, change of hair color (early graying), and splenomegaly in 
about 10–15% of patients. In addition to the above mentioned features, cobalamin defi-
ciency manifests with neurological symptoms, which include loss of joint position sense in 
the second toes, loss of vibration sense in toes and fingers, paraesthesia, hypoesthesia, tin-
gling sensation, gait abnormalities, loss of coordination, muscle weakness, spasticity, optic 
neuropathy, urinary and fecal incontinence, erectile dysfunction, dementia, memory loss. 
These neuropathies are symmetric and only affect lower extremities. Demonstrable signs 
include positive Romberg’s sign, Babinsky reflex, thermittes's sign, spasticity, hyporeflexia, 
and clonus.
Figure 1. Activated methyl cycle.
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6. Laboratory features
The laboratory features of megaloblastic anemia revolve around the laboratory investigations 
and findings of vitamin B
12
 and folate deficiencies (see Figure 2).
6.1. Blood cells
All the blood cells are affected. Erythrocytes vary markedly in size and shape (anisopoikilo-
cytosis), some are large (twice in volume of normal red cells) and oval (egg shaped) (macro-
ovalocytes) and in severe cases erythrocytes show basophilic stiplings and contain nuclear 
remnants (Howell-Jolly bodies, cabot rings). The morphologic changes are directly proportional 
to the severity of anemia. Circulating megaloblasts (i.e., nucleated red cells that failed to mature 
appropriately) are visible in circulation with hematocrit less than 20%. Anemia is typically mac-
rocytic with a mean corpuscular volume (MCV) of 100–150 FL or more. However, the macrocytic 
appearance may be masked by coexisting iron deficiency, thalassaemia trait, and inflammation. 
It is noteworthy that slight macrocytosis is the earliest sign of megaloblastic anemia. Also min-
gled with macrocytes are fragmented red cells and tear drop poikilocytes. Reticulocytopenia (a 
reticulocyte count of <1%) is a frequent finding. This occurs because of inordinate impairment of 
erythropoiesis culminating in intramedullary destruction of megaloblasts and resultant reticu-
locytopenia. This is referred to as ineffective erythropoiesis (see Figure 3).
Figure 2. Algorithm for the investigation of macrocytic anemia.
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As concerned about the leukocytes, there is a progressive reduction in white blood cells count 
but it rarely falls below 2000 cells/μL. Neutrophil hypersegmentation is another cardinal fea-
ture of megaloblastic anemia. In this case, neutrophil hypersegmentation is declared if neu-
trophils have more than the usual 3–5 nuclear segments/lobes. In other words, finding of a 
neutrophil having six or more nuclear segments or 5% of neutrophils have five or more lobes 
or in fact if most neutrophils have four or more lobes are strongly indicative of megaloblastic 
anemia. It is noteworthy that in nutritional megaloblastic anemias, hypersegmented neutro-
phils are an early sign of megaloblastosis.
Platelets vary widely in size and increased platelet distribution width (PDW) is the usual 
indicator. The complete blood count (CBC) often reveals anemia, leukopenia, and at times 
thrombocytopenia.
6.2. Serum vitamin B
12
 and folate
These tests are known to be limited by their low sensitivity and specificity, and it has been 
shown that the normal lower limits for vitamin B
12
 levels are not well defined [10]. Aside, 
these tests are expensive and not always available to the practicing clinician.
6.3. Serum B
12
 levels
Previous studies showed that vitamin B
12
 levels were found normal or elevated in myelopro-
liferative disorders, liver disease, congenital transcobalamin II deficiency, intestinal bacterial 
overgrowth, and antecedent administration of vitamin B
12
 [11]
Falsely low vitamin B
12
 levels with folate deficiency, pregnancy, use of oral contraceptives, 
congenital deficiency of serum haptocorrins, and multiple myeloma had been reported in 
Ref. [11].
6.4. Serum folate levels
Folic acid deficiency is rare where food fortification is the order of the day like in the US [12]. 
Although tissue stores may be normal, serum folate levels can decrease within a few days of 
Figure 3. Cytologic abnormalities of megaloblastic anemia on blood smear.
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dietary folate restriction [11]. Thus, patients should fast prior to testing for serum folate lev-
els, as serum folate levels increase with feeding. Mild degree of hemolysis can falsely display 
elevated serum folate levels because of high concentration of folate within the red blood cell 
(RBC) [11].
Inspite of adequate tissue store of folate, certain conditions like pregnancy, use of certain anti-
convulsant drugs and alcohol intake may also cause a decrease in serum levels of the vitamin. 
However, in vitamin B
12
 deficiency serum folate levels tend to increase, probably because 
of impairment of the methionine synthase pathway and trapping of methyltetrahydrofolate, 
which happens to be the principal form of folate in the serum [13, 14].
6.5. Red blood cell (RBC) folate
In RBC, folate level is regarded as a more reliable source of determining tissue stores of folate. 
Unlike serum folate which is affected by dietary intake, RBC folate levels remain constant 
throughout the lifespan of the cell. However, assays for measuring RBC folate levels have 
also been fraught with unreliability [14–16]. Vitamin B
12
 deficiency has been established to be 
a cause of low RBC folate levels [14, 17, 18]. It is estimated that approximately 60% of patients 
with pernicious anemia have low RBC folate levels, presumably because vitamin B
12
 is neces-
sary for normal transfer of methyl tetrahydrofolate from plasma to RBCs [13, 16, 19–21].
6.6. Bone marrow examination
The aspirated marrow is often hypercellular with striking imbalance in nuclear-cytoplasmic 
maturation often referred to as nuclear-cytoplasmic asynchrony. This asynchrony occurs 
because of progressive impaired DNA synthesis and nuclear derangements that accumulate 
with each cell division thereby slowing down nuclear replication and causes cummulative 
retardation with each step of maturation division. Therefore, the imbalance in cell growth 
becomes most apparent in matured hematopoietic cells. Sideroblasts, red cell precursors con-
taining increased number of iron granules, are increased in proportion. Also, because of ery-
throid hyperplasia, the ratio of myeloid to erythroid precursors (M/E ratio) is reversed and 
may fall to 1:1 or even lower.
In severe cases, numerous giant pronormoblasts (promegaloblasts) having an unusually 
large number of mitotic figures are present. Macrophage iron content is often increased. Even 
with the attempt of masking megaloblastic anemia by the coexistence of microcytic anemia, a 
megaloblastic anemia will usually show hypersegmented neutrophils in the blood and giant 
metamyelocytes and bands in the marrow.
Substantial disintegration of erythroblasts occurs within the marrow sinuses sequel to undue 
prolonged detention of the erythroblasts with uncondensed nuclei wherein products of 
their disintegration are scanphage by macrophages. This process is referred to as ineffective 
erythropoiesis.
It is noteworthy that a megaloblastic anemia may be misdiagnosed as acute leukemia when meg-
aloblastic anemia is very severe. In this case, the typical megaloblasts are obviously absent, and 
rather most cells available are bizarre megaloblastic pronormoblasts that dominate the marrow 
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because of lack of maturation of the erythroid series and hence raising the possibility of erythro-
leukemia. On the contrary, a patient with just macrocytosis, no anemia, and without any cellular 
abnormality on the peripheral blood film may not require bone marrow examination.
The granulocytes and megakaryocytes are equally affected by the imbalance of cell growth 
in megaloblastic anemia. Myeloid cells are generally oversized but it is the presence of giant 
metamyelocytes and giant bound forms that are actually pathognomonic of megaloblastic 
anemia. There is also complex lobular hypersegmentation (pseudo hyperdiploidy) of mega-
karyocytes. There may be megakaryocyte fragments and giant platelets in circulation.
6.7. Serum concentrations of methylmalonic acid (MMA) and homocysteine
Several important metabolic pathways require the functions of cobalamin and folate as co- 
factors. The generation of methionine from homocysteine requires the co-factors of vitamin 
B
12
 and folate. However, the production of succinyl CoA from l-methylmalonyl CoA requires 
only vitamin B
12
. The generated succinyl CoA is involved in oxidative phosphorylation reac-
tions within the cells. Therefore, early information regarding the cellular state of vitamin B
12
 and 
folate are provided by these metabolites. The serum levels of these metabolites are helpful in 
distinguishing folate from vitamin B
12
 deficiency [22, 23], whereas most patients with only folate 
deficiency have normal methylmalonic acid (MMA) or mildly elevated levels, patient with just 
vitamin B
12
 deficiency do have significantly elevated level. It is noteworthy that almost 50% of 
patients with elevation of these metabolites do have normal serum vitamin B
12
 levels. Hence, 
emphasizing the low sensitivity of serum vitamin B
12
 levels, especially when there are implicat-
ing signs and symptoms.
Overall, measuring serum MMA and homocysteine levels are well established way of differenti-
ating cobalamin deficiency from folate deficiency, whereas in cobalamin deficiency, both metab-
olites are elevated but anemic cobalamin deficient patient show more marked elevations [22, 24].
Nonanemia cobalamin deficient patients are better identified using MMA, which is far more 
sensitive than homocysteine, whereas in folate deficient patients there is marked elevation of 
homocysteine levels while serum levels of MMA are not elevated [22, 24].
Hence, measurement of serum level of these two metabolites provides a means of distinguish-
ing cobalamin from folate deficiency as well as providing a reliable degree of accuracy in 
diagnosing these deficiency states [22, 24].
However, the sensitivity of identifying patients with cobalamin deficiency is masked by 
renal dysfunction leading to a falsely elevated serum MMA [24, 25]. Also, hereditary hyper- 
homocysteinemia, where elevated homocysteine may cause confusion in diagnosing folate 
deficiency. It is recommended that measurement of MMA should be undertaken only if the 
initial levels of vitamin B
12
 and or homocysteine are abnormal.
6.8. Holotranscobalamin II (holoTC II)
When there is a discordance between vitamin B
12
 levels and its metabolites, or even before 
measuring vitamin B
12
, MMA, and/or homocysteine serum levels; holotranscobalamin II 
(holoTCII) is becoming an emerging marker that may be useful in establishing a diagnosis of 
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early vitamin B
12
 deficiency. It is also a very useful marker in cases of renal failure or myelo-
proliferative diseases in which vitamin B
12
 concentrations may be falsely elevated B
12
 [24, 25]. 
Cobalamin is transported to cell membrane receptors by holotranscobalamin II and its serum 
concentration indirectly measures the amount of available vitamin B
12
. It has been validated 
that holoTcII has greater sensitivity and specificity than serum level of vitamin although its 
routine use has not been recommended [23, 26].
Overall, the gold standard for the diagnosis of vitamin B
12
 deficiency is yet to be established. 
Meanwhile, it is recommended that with low initial vitamin B
12
 level (i.e., <150 ng/L) and 
in the setting of high clinical index of suspicion of vitamin B
12
 deficiency, a repeat of serum 
level of the vitamin is suggested preferably along with MMA and homocysteine serum levels 
[27, 28]. However, in a case of unexplained macrocytic anemia, a complete diagnostic testing 
following a specific algorithm is necessary (Table 2) [29].
Laboratory studies and diagnostic ranges Situations affecting results
Serum folate
<2 ng/mL is diagnostic
Falsely low: Pregnancy, alcohol consumption, anti-
seizure >4 ng/mL rules out deficiency drugs, temporarily 
(a few days) deficient diet (with normal)
Serum folate
2–4 ng/mL
Falsely elevated
Requires quantification of methylmalonic acid, 
homocysteine and intra-erythrocyte folate.
Single intake of folate-rich food.
Methyl-tetrahydrofolate [MTHF] and formyl-
tetrahydrofolate (FTHF)
<100–160 mg/L [Indicates deficiency]
Falsely low: Pregnancy, alcohol consumption, anti-
seizure temporarily (a few days) deficient diet (with 
normal intra-erythrocyte folate).
Compared with serum folate, less likely to alter due to 
transient variations such as dietary changes.
Falsely elevated: Single intake of folate-rich food.
Serum cobalamin
<200 pg/mL [diagnostic of deficiency]
>300 pg/mL [rules out deficiency in 95% of cases]
Falsely low: Pregnancy, folate deficiency, HIV/Aids, anti-
seizure drugs, multiply myeloma, hairy cell leukemia
200–300 pg/mL
[indicates need to quantify methylmalonic acid and 
homocysteine]
Aplastic anemia, myelodysplastic syndromes, 
paroxysmal nocturnal hemoglobinuria, Gaucher's 
disease, oral contraceptives, Intra-individual variation: 
up to 23%, idiopathic origin, laboratory error.
Methylmalonic acid (MMA)
Normal: 70–270 mmol/L
Falsely elevated: Kidney failure, methylmalonic 
acidemia. Intra-individual variation: up to 23%.
Falsely low: Use of antibiotics.
Usually elevated with comorbid cobalamin deficiency
Homocysteine
Normal: 5–14 mmol/L
Falsely elevated: Hereditary hyperhomocysteinemia: 
Intra-individual variation:
17% changes in methyl-THFR, cystathionine beta-
synthase, betaine usually elevated with comorbid 
cobalamin and folate synthesis. deficiency.
Elevated MMA and homocysteine: Cobalamin deficiency (sensitivity: 94%, specificity: 99%).
Normal MMA and homocysteine: rules out deficiency of 
both vitamins.
Normal MMA and elevated homocysteine: folate 
deficiency (sensitivity: 86%, specificity: 99%).
Table 2. Specific laboratory investigations in suspected case of folate and cobalamin deficiency.
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7. Differential diagnosis
Macrocytosis with MCV (not exceeding 110 FL) occurs in alcoholism, liver disease, hypothy-
roidism, aplastic anemia, myelodysplasia, pregnancy, and in certain disease states associated 
with a reticulocytosis (e.g., autoimmune hemolytic anemia).
8. Pernicious anemia (PA)
In pernicious anemia, the gastric parietal cells are destroyed by autoantibody and this results 
in failure or impaired production of intrinsic factor [30]. Frequently, both parietal cells and 
intrinsic factors are attacked by autoantibodies. The identification of parietal cell autoantibod-
ies is more sensitive whereas the identification of intrinsic factor autoantibody is more specific.
Studies had shown that about 70% of patients with pernicious anemia will produce detectable 
levels of such autoantibodies. The clinical symptoms of pernicious anemia developed slowly as 
B
12
 stores are sufficient for about 5 years before deficiency lead to the onset of clinical symptoms. 
Therefore, the full clinical picture of severe intramedullary hemolysis culminating in progres-
sively severe chronic anemia, along with severe neurological symptoms with demyelinisation 
leading to weakness and paraplegia occurs only rarely. Treatment with parenteral vitamin B
12
 
will lead to a rapid increase of reticulocytes (within 48–72 h) and subsequent correction of anemia.
It is more common in males than in females and has an age peak around 60 year. In perni-
cious anemia, the gastric mucosa is atrophic and the secretion of intrinsic factor is defective. 
Inflammatory infiltrate of the gastric submucosa is the earliest gastric lesion in patients with 
PA. A type A gastritis involving the fundus and sparing the antrum is the typical finding 
in a patient with autoimmune pernicious anemia. The autoantibodies both to parietal cells 
and intrinsic factor are detectable both in the serum and gastric secretions. These autoanti-
bodies particularly target the H+/K+-ATPase in the parietal cell resulting to gastric atrophy 
and achlorhydria. Studies had shown that parietal cell autoantibody is detectable in 90% of 
patients with pernicious anemia and also in 30% of first degree relatives who do not have 
pernicious anemia, and only about 2–8% of the normal population have low titer of these 
autoantibodies [31]. There are two types of anti-intrinsic factor autoantibodies. The type I 
autoantibodies blocks the binding of vitamin B
12
 to intrinsic factor and type II auto antibody, 
seen in 35–40% of patients binds to different epitope of intrinsic factor [32].
A selective malabsorption of vitamin B
12
 underlies the pathogenesis of autoimmune perni-
cious anemia. The eventual deficiency of vitamin B
12
 resulted to megaloblastic anemia and 
ineffective erythropoiesis.
9. Treatment of cobalamin deficiency
To treat a case of megaloblastic anemia, all efforts should be applied to exclude the under-
lying cause. Drug-related causes, MDS, and others should be clearly excluded. Since 
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anemia of megaloblastosis insidiously develops, patients progressively adjust to the low 
hemoglobin and hence blood transfusion is not an option except only in patients with 
severe uncompensated and life threatening anemia.
Megaloblastic anemia with established cobalamin deficiency should be given intramuscular 
cobalamin of 1000 μg daily for 2 weeks or alternatively thrice weekly for 2 weeks for six doses 
and then weekly for another six doses until hematocrit returns to normal. It is given monthly 
for life in certain cases like pernicious anemia and in partial or total gastrectomy. Patients 
with neurological and mental impairment resulting from cobalamin deficiency deserve a very 
aggressive approach.
Oral cobalamin can be adopted when there is enough evidence that the absorptive capac-
ity for cobalamin is intact. It is administered at 1000–2000 μg but a wide range of doses and 
schedules have been recommended. It is important to monitor closely for desired response 
since absorption can be variable and may be inadequate in some patients. Although intra-
muscular cobalamin is often preferable since it has the potential to bypass all abnormalities of 
cobalamin absorption. However, oral cobalamin is less expensive, better tolerated by patients, 
and preferable in patients with bleeding disorders like hemophilic patients in whom intra-
muscular injection should be avoided.
There is a need to apply multidisciplinary approach to the management of megaloblastic ane-
mia. The hematologist hold a crucial position in making diagnosis and in management while 
the neurologists should be at hand to diagnose and manage potential neurological complica-
tions. The gastroenterologists are involved in ruling out the gastroenterological causes of the 
disease by doing both upper and lower endoscopy searching for diseases like atrophic gastritis, 
carcinoma of the stomach, and terminal ileitis. Also, pediatricians are needed in diagnosing 
and managing children with inborn errors and having megaloblastosis.
9.1. Folate therapy
In folate deficiency, a full hematologic response to physiologic doses of folate at 200 μg daily dis-
tinguishes it from cobalamin deficiency pharmacologic doses of folate at 5 mg daily is required 
to achieve full hematologic response [30]. This should not be recommended as a diagnostic test 
because neurologic problems may develop in cobalamin deficient patients treated with cobala-
min alone. However, cobalamin may cause a partial response in folate deficiency [31].
Oral administration of folate is always the case except in difficult situation when parenteral 
administration may be indicated. At times folate rich diet may suffice. The dose of folate ranges 
between 1 and 5 mg daily but a higher dose is indicated in hemolytic conditions like sickle cell 
disease, hereditary elliptocytosis, hereditary spherocytosis, and in hyper-homocysteinemia. 
Food fortification with folate and supplementation are recommended to reduce the risk of 
pancreatic, cervical and colonic cancers, end stage renal disease and in elderly persons [32].
It is however noteworthy that administration of folate to individuals with Cobalamin defi-
ciency increases the risk and frequency of cobalamin-induced neurological and neuropsy-
chiatry disorders. Therefore, folate should not be instituted in patients with megaloblastic 
anemia when cobalamin deficiency has not been ruled out [33, 34].
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The response to therapy should be closely monitored using complete blood count (CBC), 
reticulocyte count, lactate dehydrogenase (LDH) levels, indirect bilirubin, hemoglobin level, 
serum potassium and serum ferritin. It is expected that LDH and indirect bilirubin should 
fall rapidly with treatment while there is evident reticulocytosis within 3–5 days and it peaks 
between 4 and 10 days. The hemoglobin is expected to rise by 1 g/dL per week and should 
rise to normal level within 2 months. It is very important to closely monitor the serum potas-
sium which falls with treatment and may result to death. Potassium supplementation should 
be given in case of hypokalemia using oral potassium supplement (slow K) Iron deficiency 
can occur because of escalated erythropoiesis and this may impede the rate of response. Iron 
therapy is equally necessary [33, 34].
A diagnostic therapeutic trial is allowed when the results of laboratory evaluation become 
ambiguous, a clinical trial of cobalamin therapy may be given. This is done only when cobala-
min deficiency has been ruled out.
Particular attention should be placed on the followings:
Hypokalemia, that is, low serum potassium, can occur in a severe megaloblastic anemia on 
treatment because of ongoing rapid restoration of erythropoiesis in the bone marrow.
Only about 1% of ingested cobalamin is absorbed through the ileal mucosa when intrinsic 
factor is deficient. Therefore, a maintenance daily dose of 1 mg may be sufficient to maintain 
steady levels in patients not willing to receive regular injections.
It is also noteworthy that neurological symptoms may be irreversible or may respond slowly 
if folic acid was given without cobalamin in combined deficiency or while dealing with very 
severe and long standing cobalamin deficiency.
Author details
Olaniyi John Ayodele
Address all correspondence to: ayodeleolaniyi8@gmail.com
Department of Haematology, College of Medicine, University College Hospital, University of 
Ibadan, Ibadan, Nigeria
References
[1] Glader B. Anemia: General aspects. In: Greer JP, Foerster J, Lukens JN, et al, editors. 
Wintrobe's Clinical Hematology. 11th ed. Baltimore, Md: Williams & Wilkins; 2004. pp. 
947-978
[2] Hoffbrand V, Provan D. ABC of clinical haematology: Macrocytic anaemias. British 
Medical Journal. 1997;314:430-433
Current Topics in Anemia42
[3] Addison T. Anaemia-disease of the supra-renal capsules. London Medical Gazette. 
1849;43:517-518
[4] Minot GR, Murphy WP. Treatment of pernicious anemia by a special diet. Blood. 
1948;3:8-21
[5] Castle WB. The effect of the administration to patients with pernicious anemia of the 
contents of the normal human stomach recovered after the ingestion of beef muscle. 
American Journal of the Medical Sciences. 1929;87:470-476
[6] Hodgkin DC, Kamper J, Mackey M, et al. Structure of vitamin B
12
. Nature. 1956;178:64-66
[7] Alpers DH. What is new in vitamin B(12)? Current Opinion in Gastroenterology. 
2005;21:183-186
[8] Chanarin I. The Megaloblastic Anaemias. 2nd ed. Oxford, England: Blackwell Scientific 
Publishers; 1979
[9] Castellanos-Sinco HB, Ramos-Penafiel CO, Santoyo-Sanchez A, Callazo-Jaloma J, et al. 
Megaloblastic anaemia: Folic acid and vitamin B
12
 metabolism. REVISTA MEDICAL 
DEL Hospital General DE MEXICO. Document descargado de http://www.elsevier.es el
[10] Ward PC. Modern approaches to the investigation of vitamin B
12
 deficiency. Clinics in 
Laboratory Medicine. 2002;22:435-445
[11] Snow CF. Laboratory diagnosis of vitamin B
12
 and folate deficiency: A guide for the pri-
mary care physician. Archives of Internal Medicine. 1999;159:1289-1298
[12] Ashraf MJ, Goyal M, Hinchey K, Cook JR. Clinical utility of folic acid testing for anemia 
and dementia screen. Journal of General Internal Medicine. 2004;19(s1):130
[13] Chanarin I. The Megaloblastic Anaemias. 2nd ed. Oxford, England: Blackwell Scientific 
Publishers; 1979
[14] Handin RI, Lux SE, Stossel TP. Blood: Principles and Practice of Hematology. 1st ed. 
Philadelphia, PA: Lippincott Williams & Wilkins; 1995. p. 1421
[15] Davidson RJ, Hamilton PJ. High mean red cell volume: Its incidence and significance in 
routine haematology. Journal of Clinical Pathology. 1978;31:493-498
[16] Lindenbaum J, Allen RH. Clinical spectrum and diagnosis of folate deficiency. In: Bailey 
LB, editor. Folate in Health and Disease. New York, NY: Marcel Dekker; 1995. pp. 43-73
[17] Handin RI, Lux SE, Stossel TP. Blood: Principles and Practice of Hematology. 1st ed. 
Philadelphia, PA: Lippincott Williams & Wilkins; 1995. p. 1421
[18] Tisman G, Herbert V. B12 dependence of cell uptake of serum folate: An explanation 
for high serum folate and cell folate depletion in B12 deficiency. Blood. 1973;41:465-469
[19] Antony AC. Megaloblastic anemias. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen 
HJ, Silberstein LE, McGlave P, editors. Hematology: Basic Principles and Practice. 3rd 
ed. New York, NY: Churchill Livingston; 2000. pp. 446-485
Megaloblastic Anemia
http://dx.doi.org/10.5772/intechopen.70063
43
[20] Jaffe JP, Schilling RF. Erythrocyte folate levels: A clinical study. American Journal of 
Hematology. 1991;36:116-121
[21] Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of 
total homocysteine in the serum of patients with cobalamin or folate deficiency detected 
by capillary gas chromatography-mass spectrometry. Journal of Clinical Investigation. 
1988;81:466-474
[22] Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity ofserum methylmalonic 
acid and total homocysteine determinations for diagnosing cobalamin and folate defi-
ciencies. American Journal of Medicine. 1994;96:239-246
[23] Solomon LR. Cobalamin-responsive disorders in the ambulatory care setting: Unreliabil-
ity of cobalamin, methylmalonic acid, and homocysteine testing. Blood. 2005;105: 
978-985
[24] Alpers DH. What is new in vitamin B
12
? Current Opinion in Gastroenterology. 2005;21: 
183-186
[25] Lloyd-Wright Z, Hvas A, Moller J, Sanders TA, Nexo E. Holo-transcobalamin as an indi-
cator of dietary vitamin B12 deficiency. Clinical Chemistry. 2003;49:2076-2078
[26] Nilsson K, Isaksson A, Gustafson L, Hultberg B. Clinical utility of serum holo-transco-
balamin as a marker of cobalamin status in elderly patients with neuropsychiatric symp-
toms. Clinical Chemistry and Laboratory Medicine. 2004;42:637-643
[27] Robinson AR, Mladenovic J. Lack of clinical utility of folate levels in the evaluation of 
macrocytosis or anemia. American Journal of Medicine. 2001;110:88-90
[28] Andres E, Fothergill H, Mecili M. Efficacy of oral cobalamin (vitamin B12) therapy. 
Expert Opinion on Pharmacotherapy. 2010 Feb;11(2):249-256. [Medline]
[29] Robinson AR, Mladenovic J. Lack of clinical utility of folate levels in the evaluation of 
macrocytosis or anemia. American Journal of Medicine. 2001;110:88-90
[30] Antony AC. Megaloblastic Anemias. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop 
HE, Weitz JI, Anastasi J. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, 
PA: Elsevier; 2013. pp. 473-504
[31] Wang YH, Yan F, Zhang WB, et al. An investigation of vitamin B12 deficiency in elderly 
inpatients in neurology department. Neuroscience Bulletin. 2009 Aug;25(4):209-215. 
[Medline]
[32] Hoffbrand AV. Megaloblastic anemias. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, 
Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19th ed. New 
York, NY: McGraw-Hill Education; 2015
[33] Bunn HF. Vitamin B12 and pernicious anaemia-The dawn of molecular medicine. The 
New England Journal of Medicine. 2014;370:773-776. DOI: 10.1056/NEJM,Mcibr 1315544
[34] Schick P, Talaesera F, Sacher RA, Besa E, et al. Megaloblastic Anaemia in Medscape 
update 2017 (Jan). emedicine.medscape.com/article/204066-overview
Current Topics in Anemia44
